$XGN News
Last published 3d ago
- 3d agoXGNEXAGEN INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoXGNExagen Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswireThird Quarter Revenue Grew 7% to $18.4 Million
- 3d agoXGNEXAGEN, INC. Q3 2026 EARNINGS CALL - EXAGEN INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Exogen third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and ans
- 2w agoXGNExagen Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the
- 2w agoXGNExagen to Announce Third Quarter Financial Results on November 10, 2026GlobeNewswireCARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the
- 3mo agoXGNEXAGEN, INC. CG 46TH ANNUAL GROWTH CONFERENCE - EXAGEN INCEarnings Call TranscriptsHi, welcome to the Canaccord Genuity Growth Conference. I'm Kyle Mixon. I cover lifetime solutions and diagnostics for Canaccord. I'm pleased to welcome you to a Fireside Chat with Exogen here with us today. Exogen is a
- 3mo agoXGNCG 46TH ANNUAL GROWTH CONFERENCE - EXAGEN INCEarnings Call TranscriptsHi, welcome to the Canaccord Genuity Growth Conference. I'm Kyle Mixon. I cover lifetime solutions and diagnostics for Canaccord. I'm pleased to welcome you to a Fireside Chat with Exogen here with us today. Exogen is a
- 3mo agoXGNExagen Q2 2026 Earnings Call - EXAGEN INCEarnings Call TranscriptsGreetings and welcome to the Exogen, Inc. Q2, 2026 earnings call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. Should anyone require o
- 3mo agoXGNExagen Inc. Reports Second Quarter 2026 Financial ResultsGlobeNewswireAchieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million
- 3mo agoXGNExagen Inc. to Participate in Upcoming Investor ConferenceGlobeNewswireCARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord
- 3mo agoXGNExagen to Announce Second Quarter Financial Results on August 4, 2026GlobeNewswireCARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market
- 5mo agoXGNExagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE LupusGlobeNewswireUniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive
- 6mo agoXGNExagen Q1 2026 Earnings Call - EXAGEN INCEarnings Call TranscriptsGreetings, and welcome to the Exogen First Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require
- 6mo agoXGNExagen Inc. Reports First Quarter 2026 ResultsGlobeNewswireCARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent
- 6mo agoXGNExagen Inc. to Announce First Quarter Financial Results on May 11, 2026GlobeNewswireCARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market
- 8mo agoXGNExagen Q4 2025 Earnings Call - EXAGEN INCEarnings Call TranscriptsGreetings. Welcome to Exogen Incorporated's fourth quarter 2025 earnings call. At this time, all participants are in listen-only mode. Question and answer session will follow the formal presentation. If anyone should req
- 8mo agoXGNExagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 ResultsGlobeNewswireRecord full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) --
- 8mo agoXGNExagen Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank
- 8mo agoXGNExagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026GlobeNewswireCARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the
- 10mo agoXGNExagen Inc. Announces Select Preliminary 2025 Financial ResultsGlobeNewswireCARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year
- 1y agoXGNExagen Inc. Reports Strong Q3 2025 ResultsGlobeNewswireCARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent
- 1y agoXGNExagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology ConvergenceGlobeNewswireCARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's
- 1y agoXGNExagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025GlobeNewswireCARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the
- 1y agoXGNExagen Inc. to Participate in Third Quarter Investor ConferencesGlobeNewswireCARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor
- 1y agoXGNExagen Inc. (XGN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoXGNExagen Inc. Reports Strong Q2 2025 ResultsGlobeNewswireCARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent
- 1y agoXGNExagen Inc. Appoints Chas McKhann to Board of DirectorsGlobeNewswireCARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors,
- 1y agoXGNExagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025GlobeNewswireCARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market
- 1y agoXGNMichael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune DiagnosticsGlobeNewswireCARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific
- 1y agoXGNExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesGlobeNewswireCARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its
- 1y agoXGNExagen Inc. Prices Public Offering of Common StockGlobeNewswireCARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of
- 1y agoXGNExagen Inc. Announces Proposed Public Offering of Common StockGlobeNewswireCARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its
- 1y agoXGNExagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeGlobeNewswireCARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent
- 1y agoXGNExagen Inc. Announces Senior Secured Credit Facility with Perceptive AdvisorsGlobeNewswire$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen
- 1y agoXGNExagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025GlobeNewswireCARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on
- 1y agoXGNExagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsGlobeNewswireDelivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD
- 1y agoXGNExagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025GlobeNewswireCARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market
- 1y agoXGNExagen Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
- 1y agoXGNExagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial ResultsGlobeNewswireNew biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
- 1y agoXGNExagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTDGlobeNewswireCARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that
- 1y agoXGNExagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformGlobeNewswireCARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE)
- 1y agoXGNExagen Inc. to Participate in Fourth Quarter Investor ConferencesGlobeNewswireCARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor
- 2y agoXGNExagen, Inc. (XGN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoXGNExagen Inc. Reports Third Quarter 2024 ResultsGlobeNewswireExpanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD, Calif., Nov.
- 2y agoXGNExagen to Announce Third Quarter 2024 Results on November 12, 2024GlobeNewswireCARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024, before the market opens
- 2y agoXGNExagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology ConvergenceGlobeNewswireCARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's
- 2y agoXGNExagen Inc. to Participate in the 2024 Cantor Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference,
- 2y agoXGNExagen, Inc. (XGN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoXGNExagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record PerformanceGlobeNewswireCARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights:
- 2y agoXGNExagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewswireCARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth